Index by author

August 1, 2021; Volume 62,Issue 8

  1. Eersels, Jos L.E.

    1. Phase I Trial of <sup>131</sup>I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
      Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
      Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1097-1105; DOI: https://doi.org/10.2967/jnumed.120.255679

  2. Eiber, Matthias

    1. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using <sup>19</sup>F/<sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA I&amp;T
      Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
      Nahid Yusufi, Alexander Wurzer, Michael Herz, Calogero D’Alessandria, Benedikt Feuerecker, Wolfgang Weber, Hans-Jürgen Wester, Stephan Nekolla and Matthias Eiber
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1106-1111; DOI: https://doi.org/10.2967/jnumed.120.254516
    2. Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and Tumor Positivity
      Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and Tumor Positivity
      Markus Kroenke, Lilit Mirzoyan, Thomas Horn, Jan C. Peeken, Alexander Wurzer, Hans-Jürgen Wester, Marcus Makowski, Wolfgang A. Weber, Matthias Eiber and Isabel Rauscher
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1082-1088; DOI: https://doi.org/10.2967/jnumed.120.251447

  3. Elsinga, Philip H.

    1. Synthesis and Evaluation of <sup>18</sup>F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-<sup>18</sup>F-Fluoro-5α-Dihydrotestosterone
      Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone
      Inês F. Antunes, Rutger J. Dost, Hilde D. Hoving, Aren van Waarde, Rudi A.J.O Dierckx, Douwe F. Samplonius, Wijnand Helfrich, Philip H. Elsinga, Erik F.J. de Vries and Igle J. de Jong
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1140-1145; DOI: https://doi.org/10.2967/jnumed.120.253641
    2. Mapping Arginase Expression with <sup>18</sup>F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids
      Mapping Arginase Expression with 18F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids
      Gonçalo S. Clemente, Inês F. Antunes, Santosh Kurhade, Mariska P.M. van den Berg, Jürgen W.A. Sijbesma, Aren van Waarde, Rogier C. Buijsman, Nicole Willemsen-Seegers, Reinoud Gosens, Herman Meurs, Alexander Dömling and Philip H. Elsinga
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1163-1170; DOI: https://doi.org/10.2967/jnumed.120.255968

  4. Eppard, Elisabeth

    1. Evaluation of Safety and Dosimetry of <sup>177</sup>Lu-DOTA-ZOL for Therapy of Bone Metastases
      Open Access
      Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases
      René Fernández, Elisabeth Eppard, Wencke Lehnert, Luis David Jiménez-Franco, Cristian Soza-Ried, Matías Ceballos, Jessica Ribbeck, Andreas Kluge, Frank Rösch, Marian Meckel, Konstantin Zhernosekov, Vasko Kramer and Horacio Amaral
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1126-1132; DOI: https://doi.org/10.2967/jnumed.120.255851

  5. Everaert, Hendrik

    1. Phase I Trial of <sup>131</sup>I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
      Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
      Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts
      Journal of Nuclear Medicine August 1, 2021, 62 (8) 1097-1105; DOI: https://doi.org/10.2967/jnumed.120.255679
Back to top

In this issue